The 10 billion bid by Novo Nordisk for obesity drug developer Metsera is under scrutiny for possibly breaching US antitrust regulations The Federal Trade Commission cautioned that executing the deal without a prior review could violate the law complicating Novos ambitions in the competitive obesity drug market
